Nutriband Inc. (NASDAQ:NTRB - Get Free Report)'s share price traded down 8.1% on Tuesday . The stock traded as low as $5.52 and last traded at $5.82. 18,083 shares were traded during mid-day trading, a decline of 51% from the average session volume of 36,552 shares. The stock had previously closed at $6.33.
The company has a quick ratio of 6.36, a current ratio of 6.57 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $5.69 and a 200 day moving average price of $5.38. The firm has a market capitalization of $64.23 million, a PE ratio of -7.56 and a beta of 1.12.
Nutriband (NASDAQ:NTRB - Get Free Report) last released its earnings results on Tuesday, September 3rd. The company reported ($0.12) earnings per share for the quarter. The firm had revenue of $0.44 million during the quarter. Nutriband had a negative net margin of 401.39% and a negative return on equity of 66.60%.
An institutional investor recently bought a new position in Nutriband stock. Virtu Financial LLC acquired a new stake in Nutriband Inc. (NASDAQ:NTRB - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,862 shares of the company's stock, valued at approximately $58,000. Virtu Financial LLC owned about 0.12% of Nutriband at the end of the most recent quarter. 19.70% of the stock is currently owned by hedge funds and other institutional investors.
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.